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In my doctoral work, I have designed bioconjugates that can elicit desired cellular 
responses – cellular effectors. I have been particularly interested in using multivalent 
interactions, involving the simultaneous binding of multiple receptors to multiple ligands. 
In this dissertation, I have designed synthetic multivalent cellular effectors to use as 
vaccines and to direct stem cell fate. First, I have developed multivalent scaffolds to be 
used as a “universal” influenza vaccine based on virus-like particles (VLPs) displaying the 
influenza antigen hemagglutinin (HA). By site-specific bioconjugation, we have controlled 
the orientation of HA on the surface of the VLPs to make the conserved stalk region more 
accessible to the immune system. We have seen an enhanced stalk-directed immune 
response, and protection in mice against a challenge with influenza viruses presenting a 
chimeric hemagglutinin.  
Using a similar strategy, we have developed vaccine constructs for Respiratory 
Syncytial Virus (RSV) that we are using to understand the importance and efficacy of a 
newly discovered antigenic site Ø (site Ø). We have already demonstrated the ability to 
tune the binding of anti-site-Ø antibodies to multivalent scaffolds presenting RSV antigens 
and immunization experiments with these scaffolds are currently underway. We have also 
developed a novel strategy for nanopatterning protein antigens to guide the immune 
response toward and away from desired epitopes. We have demonstrated the concept using 
green fluorescent protein (GFP) as a model antigen and are extending the concept to other 
antigens. This method could be broadly applicable to direct immune responses to conserved 
and highly efficacious epitopes on protein antigens.  
 x 
I have also designed multivalent ligands that can modulate signaling pathways (e.g., 
Wnt and Eph signaling pathways). I have generated polypeptide-based scaffolds that can 
explicitly control the valency of multivalent conjugates as well as the inter-ligand spacing. 
In collaboration with UC Berkeley, we have shown that these polypeptide scaffolds can be 
used to induce stem cell signaling and that controlling the valency and spacing affects Eph-
ephrin signal potentiation. We are also developing multivalent molecules comprised of 
antibody fragments bound to polymeric scaffolds to be effective at modulating Wnt 
signaling and that can potentially be used as therapeutics to modulate stem cell 
differentiation. Modulating the Wnt pathway has been difficult in the past due to the 
difficulty of expressing the Wnt ligand and the complexity of a dual-receptor-mediated 
signaling pathway. I have established the protocols that will be needed to validate the initial 
multivalent conjugates that will be made. 
Using protein engineering tools, I have developed multivalent molecules that can 
direct cellular responses and have shown they are effective in stimulating immune and 
stem-cell signaling events. The scaffolds that I have developed can be used in other vaccine 
design and stem cell proliferation studies. The general application of nanopatterning 
protein antigens has already been applied to several other systems in our lab and we 
hypothesize that it will be broadly applicable in future antigen design studies. Thus, the 
work presented in this thesis will stand as a foundation for future studies in vaccine design 
and cell signaling studies.  
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CHAPTER 1. INTRODUCTION 
Multivalent interactions – the simultaneous binding of several ligands on one moiety 
to several receptors on another – are ubiquitous throughout biology1. They range in size 
from protein-protein interactions at the nanometer scale to cell-cell interactions stretching 
over micrometers. The function of multivalency can vary from increasing affinity of 
ligands to targets to tuning response levels in signaling cascades or creating large contact 
surfaces between moieties1. For example, the affinity (or avidity) of a peptide ligand for a 
target protein can increased by over 5 orders of magnitude using multivalency2,3. The 
functions of multivalency are not mutually exclusive and biological and synthetic systems 
can benefit from the implementation of multiple modes of action. Thus, mimicking this 
natural phenomenon is a promising approach to developing novel therapeutics and 
bioactive molecules. 
1.1 Multivalency in Biology Example: Influenza 
A prime example of multivalent interactions in biology is the binding of a virus to a 
cell. Figure 1 depicts the binding of an influenza virus to a respiratory tract cell4. The 
hemagglutinin protein on the virus binds to sialic acid residues on the surface of cells. This 
interaction in its monovalent form has a millimolar dissociation constant (Kd)5. However, 
viral binding to sialic acid monomers shows a Kd  ~ 10 µM6, and binding the virus to 
synthetic molecules presenting sialic acid in a multivalent fashion (somewhat analogous to 





Figure 1. Attachment of influenza virus to cell surface. Viral attachment is mediated by the 
multivalent binding of hemagglutinin on the virus to sialic acid residues on the cell membrane. 
There are roughly 400 HA trimers on the viral envelope and several thousand sialic residues on cell 
surfaces. Image reprinted from http://www.cdc.gov/flu/images.htm 
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The multivalent nature of the virus also has ramifications for the immune response 
of the infected individual. B-cells, whether naive or memory related, carry antibodies on 
their surfaces as part of the B-cell receptor complex used to identify immunogens. Upon 
multivalent binding, the B-cell receptors are clustered together and induce a signaling 
cascade within the cells (Figure 2) that triggers a larger immune response9. Thus, not only 
does multivalent binding enhance the binding of B-cells to their immunogens but there is 
an overall activation of the cell in response. 
1.2 Engineered Multivalency: Targeting, Binding, and Inhibition 
As shown with influenza, multivalent interactions can increase the affinity of a 
ligand for its target dramatically. Thus, synthetic multivalent molecules are well poised to 
be used for targeting and adhesion. Further, pathogen inhibitors can be improved by 
mimicking and disrupting the multivalent interactions that pathogens use to bind to their 
hosts. Several reviews highlight how nanoparticle- and polymer-based multivalent displays 
find therapeutic usage1,10–18. Figure 3 highlights a few recent papers that demonstrate how 
the enhanced binding of multivalent systems can be beneficial for therapeutics.  
In Figure 3A, Rhee et al. were able to target cells expressing the CD22 receptor by 
covalently attaching a glycan to the surface of a virus-like particle (VLP)19. While 
unconjugated VLPs did not bind to cells, the glycan coated VLPs selectively bound to 
target cells and were able to be used as photodynamic killing agents. In Figure 3B, Kang 
et al. developed a modular platform that can display any antibody of choice on a multivalent 




Figure 2. B-cell activation upon multivalent binding of ligand. The antibodies on the surface of B-
cells cluster together upon ligand binding. The clustering of the intracellular domain of the B-cell 







Figure 4. Examples of synthetic multivalent molecules for targeting, binding and inhibition. (A) 
Glycan directed targeting of VLPs for photodynamic killing (Rhee, 2012)19. (B) Nanoparticle-based 
multivalent display of targeting antibodies (Kang, 2012)20. (C) Multivalent DNA aptamer hydrogel 
for capturing cancer cells (Zhao, 2012)21. (D) β-cyclodextrin-based inhibitor of anthrax toxin (Joshi, 






Fc-binding peptide. These nanoparticles were subsequently targeted to HER2 expressing 
cancer cells as a proof of principle. 
Multivalent polymers have also been used to enhance avidity of binding ligands. 
Figure 3C shows how Zhao et al. created multivalent networks of protein tyrosine kinase 
7 (PTK7)-binding aptamers based on the biopolymer DNA21. PTK7 is overexpressed on 
certain leukemia cells and served as a multivalent handle to pull down cancer cells from 
whole blood. Joshi et al. used β-cyclodextrin to develop anthrax toxin inhibitors (Figure 
3D)2. The multivalent display of the peptide ligand decreased the half-maximal inhibitory 
concentration (IC50) of the inhibitor by over five orders of magnitude. 
1.3 Engineered Multivalency: Cellular Effectors 
Another niche that multivalent molecules fill is that of cellular effectors. As exemplified 
in B-cell-antigen interactions (Figure 2), many cellular processes are controlled by the 
clustering of membrane bound receptors1,22–24.  Again, this natural phenomenon has been 
copied by researchers to both study and artificially modulate various signaling cascades 
including those involved in immune responses25–30 and cellular differentiation and 
growth31–35. Webber et al. designed a vascular endothelial growth factor-based peptide 
amphiphile (VEGF-PA) that assembled into nanofiber gel networks (Figure 4A)35. In an in 
vivo chicken chorioallantoic membrane (CAM) assay the VEGF-PA showed markedly 
enhanced blood vessel generation compared to the peptide alone; the multivalent display 
of the VEGF peptide increased angiogenesis by almost 4-fold. In another study, Conway  
et al. conjugated ephrin-B2 to hyaluronic acid to cluster Eph receptors and induce neural 
stem cell differentiation into dopaminergic neurons (Figure 4B)31. They saw that the 
multivalent ephrin-B2 promoted differentiation better than monovalent and Fc-conjugated 
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bivalent ephrin-B2. Conway also found that the density of ephrin-B2 proteins conjugated 
to the linear polymer backbone correlated with downstream signaling strength. 
 
  
Figure 4. Multivalent molecules as cellular effectors. (A) VEGF-peptide amphiphiles (VEGF-PA) 
were designed to assemble into nanotubes and formed network hydrogels (Webber, 2011)35. Blood 
vessel density correlated to angiogenesis in an in vivo CAM assay. (B) Ephrin-B2 was conjugated 
to hyaluronic acid polymers and induced receptor clustering (Conway, 2013)31. Differentiation of 
rat neural stem cells was visualized by immunostaining cell specific markers. in vitro and in vivo. 




CHAPTER 2. DIRECTING THE IMMUNE RESPONSE TO 
CONSERVED EPITOPES ON INFLUENZA HEMAGGLUTININ 
THROUGH ANTIGEN ORIENTATION 
2.1  Introduction 
 It is estimated that influenza epidemics cause 250000-500000 deaths worldwide 
each year36. The global health challenge influenza viruses present is due in part to their 
ability to rapidly mutate to evade the immune system. Moreover, influenza vaccines elicit 
antibody responses directed primarily to the globular head domain on the hemagglutinin 
protein (HA)37–39. This immunodominant epitope on HA varies widely from strain to strain 
and across subtypes of influenza, thus necessitating seasonal Influenza vaccines40. HA does 
have exposed conserved domains, but the high immunogenicity of the globular head region 
that protrudes away from the virus leads to very few antibodies being raised against the 
conserved stalk domain41.  
 Figure 5 shows several antibodies binding to HA42. Four of these, HC19, HC45, 
HC63, and HC151, bind to the head region and are strain specific. However, CR6261, 
which binds to the stalk of HA, is broadly neutralizing. Similarly, stalk-specific antibodies 
isolated from human sera show broad neutralization activity43–45. The stalk of HA, which 
is needed for membrane fusion after the virus has adhered to the cell, is highly conserved 
across various subtypes of Influenza. Thus, this epitope is less likely to undergo antigenic 
drift unlike the nonessential head domain. These facts suggest that if we can target the 
immune response to the stalk region of HA instead of the head domain, then we could elicit 
broadly neutralizing antibodies against influenza that could be active from year to year and 
end the need to receive seasonal flu vaccines. Indeed, because stalk-specific antibodies can 




Figure 5. Structure of strain specific and broadly neutralizing antibodies to HA42. HA (surface 
structure) binds to several strain specific antibodies at its globular head domain. CR6261, however, 
binds to the highly conserved stalk region and is thus broadly neutralizing. Reprinted with 
permission from Ekiert, 200942. 
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administrations42,4643,44,47,48 have led many researchers to try and develop vaccines that 
induce stalk specific immune responses. 
 One effort to generate stalk specific immune responses is by using chimeric HA 
proteins46,49. In brief, the stalk domain of HAs that are of concern for seasonal epidemics 
or pandemics are fused to the head domains of rare HAs that our immune systems are naïve 
to. Sequential immunizations with repeated HA stalks and changing HA heads lead to 
affinity maturation of antibodies specific to the stalk domain of HA.  This vaccination 
approach yield antibodies that are effective against heterosubtypic viral challenges (i.e., 
antibodies generated against H1 are effective against H5 viruses). However, the display of 
these chimeric HAs in terms of traditional vaccines (rosettes on a virion) could lead to 
lower stalk-directed response than desirable. 
 In an effort to display HA with greater accessibility to the stalk domain, Kanekiyo 
et al fused HA to ferritin, which self assembles into nanoparticles50. The geometry of the 
ferritin particle makes the stalk of HA more accessible; causatively, these nanoparticle-
based vaccines elicited antibodies that could neutralize several influenza strains within the 
same subtype.  
 In order to remove all head specific antibodies, recent reports have shown the 
ability to stabilize the stalk of HA in absence of the head domain51–58. Implagliazzo et al.51 
and Yassine et al.52 both recently and independently reported stabilized headless- HAs that 
elicited stalk reactive antibodies active against influenza of different subtypes. Potential 
drawbacks of this approach include that by cutting off the head domain regions of the stalk 
that are blocked during infection are now available for antibody binding, and that 
generating these headless HAs has been extremely difficult and the fact that it has worked 
for one subtype does not mean that it will be feasible with different subtypes and groups 





Figure 6. Inverting HA orientation. The HA ectodomain will be attached to a nanoparticle (virus-
like particle) in the inverse orientation from that of the native virus. The inverted orientation 







 We hypothesized that by reversing the orientation of HA on the surface of a vaccine 
(illustrated in Figure 64) we can increase the relative immunogenicity of the stalk region 
and elicit broadly neutralizing antibodies. In this way, we will keep the native sequence of 
the virus, and the only antigen that is presented to the immune system is the antigen of 
choice. Our method for displaying HA in this way is based on virus-like particles (VLPs). 
VLPs have been targeted for vaccine development by many researchers 59–61. We have used 
the bacteriophage MS2 to display Hemagglutinin in both native and inverse orientations 
and have seen directly that reversing the orientation of HA generates a more protective 
immune response.  
2.2 Materials and Methods 
2.2.1 Generation of VLPs 
MS2 VLPs were chosen as a scaffold because they have been shown to tolerate 
short insertions in the AB loop of the coat protein62. We generated a single chain dimer of 
MS2 with the avitag (GLNDIFEAQKIEWHE) inserted into the AB loop at residue 13 of 
the second monomer in the dimer chain. The coding DNA was E coli optimized and 
synthesized by Genscript and cloned into the pet28b between Nde1 and XhoI. pET28b-
MS2AviDimer and pAcm-BirA (Avidity, LLC) were co-transformed into BL21(DE3) and 
grown in 2xYT media with 50 µg/ml kanamycin and 25 µg/ml chloramphenicol. 5 ml 
overnight cultures were added to 1 L 2xYT media. To induce expression and in vivo 
biotinylation, 1 mM IPTG and 50 µM D-biotin were added at OD=0.5-0.8 and cells were 
allowed to grow overnight at 30oC. Cells were lysed by sonication and VLPs were purified 
on the GE Capto Core 700 resin. Purified MS2AviDimer was confirmed by gel 
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electrophoresis and biotinylation was confirmed by western blot, and VLP assembly was 
confirmed by dynamic light scattering and size exclusion chromatography.  
2.2.2 Expression of HA 
Influenza hemagglutinin was expressed and purified as previously described63. 
Insect optimized DNA was synthesized and cloned into pFastBac-Dual by General 
Biosystems under the p10 promoter. Insect optimized DNA coding for the biotin ligase 
BirA was cloned into the HA containing vectors under the polyhedron promoter to allow 
for in vivo biotinylation. Plasmids received were then transformed into DH10Bac 
competent cells as per manufacturer protocol. DNA was isolated via the PureLink miniprep 
protocol and used to generate baculovirus as described. Protein expression was carried out 
in Hi5 cells and proteins were purified by IMAC followed by SEC.  
2.2.3 Adding streptavidin/HA to VLPS 
Vaccine assembly was done in a two-step process. First, MS2 VLPs were added 
dropwise to 10-fold molar excess of 1 mg/ml streptavidin (Rockland) relative to avitag 
sites. After stirring for 1 hr at room temperature, the mixture was loaded onto a stepwise 
sucrose gradient (equal volumes 4%, 10%, and 30% sucrose in PBS) and spun at 31,000 
rpm for 16-18 hrs in a SW-32Ti rotor. The top 29mL of the gradient were discarded and 
the pelleted streptavidin-coated VLPs were resuspended followed by desalting through a 
PD10 column. Then, HA was added to the streptavidin VLPs in a 2:1 molar ratio to 
streptavidin and incubated with stirring for 1 hr at room temperature. The assembled 
vaccines were purified again by sucrose gradient and the loading of HA onto the final 
vaccine constructs was verified by western blot.  
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2.2.4 Vaccine Characterization 
Vaccines were characterized by several methods. SDS-PAGE and western blots were used 
to confirm the purity and presence of the vaccine subunit proteins. Transmission electron 
microscopy was performed by coating proteins on formvar treated Cu grids and negative 
staining with uranyl formate. For gold labeling, streptavidin VLPs were mixed with biotin-
gold nanoparticles and then coated and stained. Images were collected on a Hitachi 
HT7700. Dynamic Light Scattering was performed on a Wyatt Dynastar reader.  
2.2.5 Immunizations and Viral Challenge 
Immunizations with vaccines were carried out by Florian Krammer at the Mount Sinai 
School of Medicine. In short, poly I:C was added to the VLP samples immediately prior to 
injection. 5 µg of HA were injected per mouse intramuscularly in a volume of 55 µl. The 
vaccinations happened every 21 days. All vaccines were tested with n=5 female BALB/C 
mice 6-8 weeks old. Viral challenges were performed by challenging the mice with 2.5 
LD50 of an cH5/1N1 influenza virus. Weights were tracked and mice were euthanized when 
body weight dropped below 75% of initial. All animal experiments were performed in 
accordance with MSSM standard ethics protocols. 
2.3 Results 
2.3.1 Generation of VLP vaccines 
We have developed a vaccine platform based on virus-like particles (VLPs) made 
from the bacteriophage MS2. Figure 7 outlines our approach to use MS2 VLPs as vaccine 




Figure 7. Development of VLP-based influenza vaccines. Single-chain MS2 coat protein dimers 
self-assemble into 27nm VLPs with 90 dimers. The biotin VLPs are bound to streptavidin and result 
in a streptavidin coated nanoparticle. Finally, HA biotinylated at either the tail end (native display, 
top) or head domain (reverse display of HA, bottom) is bound to make vaccines. Images including 
assembled VLPs are to scale. PDB IDs: 1MSC, 1STP, 2MS2, and 1RU7. 
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MS2 coat protein at the AB loop62. These proteins are both biotinylated and assembled into 
VLPs in vivo by co-expression with a Biotin ligase enzyme. Once self-assembled, 90 
dimers form a roughly 27 nm particle with icosahedral symmetry64. The purity and 
assembly of the VLPs were verified by SDS-PAGE, DLS and TEM (Figure 8). VLPs were 
coated on transmission electron microscopy (TEM) grids and negatively stained. The 
particles show a diameter of roughly 30 nm which is consistent with the 27 nm diameter 
reported (Figure 8)64. 
The VLPs were then coated with excess streptavidin. Streptavidin is tetravalent in 
binding biotin, with a Kd of close to 10-14 M; it is one of the strongest non-covalent bonds 
known65. The biotin binding sites are available on opposite sides of streptavidin, and after 
quenching the surfaces of the VLPs, the particles become reactive to biotin again. 
Streptavidin coated VLPs were purified from free protein by ultracentrifugation through a 
sucrose cushion. The coating was confirmed to have equal mass of streptavidin and MS2 
protein by SDS-PAGE and densitometry, which corresponds to the surface of the particles 
being completely covered. Furthermore, DLS confirmed an increase in the average particle 
diameter and TEM revealed that biotinylated gold particles bound to the surface of the 
streptavidin coated VLP (Figure 9). We have concluded that this behavior was biotin-
mediated because when particles were quenched with excess biotin no attachment was seen 
(data not shown).  
The activated scaffold was then ready to be coated with biotinylated HA antigen. 
We expressed and purified HA as previously described63. An Avitag sequence was 
incorporated either in the head domain or at the tail end of HA to allow for site-specific 




Figure 8. Characterization of MS2 VLPs. (A) Purified protein was run on SDS-PAGE to verify 
purity. (B) Size measurements were made with dynamic light scattering. (C) VLPs were imaged 



























Figure 9. Characterizing Streptavidin-VLPs. (A) Commassie stained SDS-PAGE reveals that 
streptavidin is bound to the MS2 particles. (B) DLS shows an increase in average diameter of the 
particles. (C) TEM after negative staining shows particles retain structure and have a protein coat 
on their surface. (D) Particles were mixed with biotin-labeled gold nanoparticles and coated on a 

























HA through SEC-MALS. We were able to express and purify HA to homogeneity and 
confirmed that we did assemble trimeric protein (see Figure 10). ELISA analysis further 
revealed that both biotinylated versions of HA bound to a conformationally specific 
antibody, thus also verifying proper folding.  
Coating the activated VLPs with either version of biotinylated HA trimer resulted 
in two testable vaccines, one presenting HA in the reverse orientation (head biotinylated), 
and one presenting HA in the native conformation, similar to the natural virus (HA 
biotinylated at the stem). VLP-HA conjugates were also analyzed by TEM (Figure 11). 
While exact characterization of the HA on the surface is difficult, the particles do appear 
to have a thicker protein shell than VLPs alone and there are proteins protruding from the 
surface. Based on quantification tests by BCA assays and semi-quantitative western blots, 
we generally achieved 10 HA trimers per VLP. This corresponds to about 350 nm2 per HA 
trimer on the VLP surface compared to roughly 60 nm2 per HA trimer on the viral 
envelope66; thus, HA on the VLP scaffolds is much less densely packed than on the virus. 
2.3.2  Immunizations and viral challenges 
We then sought to test if these VLP vaccines could induce the production of broadly 
neutralizing antibodies. In the labs of our collaborators at the Mt. Sinai School of Medicine, 
the first vaccination course performed used three vaccinations carrying an H1 subtype of 
HA. A viral challenge was performed using a chimeric HA with the stalk of H1 but the 
head domain of H5 (Figure 12). This challenge probed for antibodies that were generated 
against the stalk of HA specifically. Mice were protected from the chimeric H5/1 virus 




Figure 10. Expression of biotinylated HA. (A) SDS-PAGE of biotinylated HA after purification. 
Lanes: M-marker, 1- Head-biotinylated HA, 2 – tail biotinylated HA. (B) ELISA of expressed HA 
with three anti-HA antibodies, py102 and pr8 bind to the head domain of HA and are non-



























Figure 11. Characterization of HA coated vaccines. (A) TEM of full vaccine particles reveal a large 
protein coat, consistent with HA attachement. (B) A representative western blot used to detect and 











Figure 12. Vaccination and viral challenge after 3 injections. Full length H1 was used as the 
immunogen on VLPs in three injections. A chimeric H5/1 virus having an H5 head and H1 stalk 
was used to challenge. Data points on the right are the average of 5 mice. Tail tag refers to native 
presentation of HA, Head tag the inverted presentation of HA. 
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immune response whether it was proximal or distal to the surface of the VLP. This is not 
surprising as a recent influenza vaccine based on ferritin particles saw a similar response20. 
We hypothesize that because the HA particles are about 5- to 6-fold less packed on the 
VLP as they are on the virus they are more accessible to the immune system than when 
presented from the surface of the influenza virus. Serology tests suggested that there was a 
slight difference in the generation of stalk-specific antibodies after two injections that was 
then lost after the third injection.  
This encouraged us to proceed with another round of vaccinations, this time only 
with two injections (Figure 13). The difference in protection was clear after two 
immunizations. Mice immunized with HA in the reverse orientation were fully protected 
while only 60% of the group immunized with HA in the native conformation survived. 
Thus, the generation of anti-stalk antibodies appears be promoted better by orienting the 
stalk outward than when the stalk is partially covered by the head domain.  
2.4 Discussion 
We have developed VLP-based scaffolds that can be used to display any biotinylated 
protein. By site-specifically biotinylating proteins by inserting the epitope recognized by 
the Biotin ligase enzyme BirA, antigenic proteins can be loaded onto the scaffold in a 
defined orientation. This streptavidin coated particle is similar to other plug and play 
scaffolds that allow for any antigen of choice to be loaded67. VLP scaffolds do have the 
potential challenge associated with generating antibodies against the scaffold itself rather 





Figure 13. Chimeric H5/1N1 viral challenge after 2 injections. (A) Percent survival of the 5 mice in 
each group challenged. Tail tag refers to native presentation of HA, Head tag the inverted 
presentation of HA. (B) The average weight of living mice was normalized for initial weight and 
plotted for each vaccine construct. 
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these scaffolds are well suited to generating strong immune responses even in the absence 
of adjuvant59,67,69,70.  
We have used this multivalent streptavidin scaffold to display an H1 subtype HA 
from influenza in both the native orientation which leads the globular, immunodominant 
head to be highly exposed and in the inverse orientation resulting in the highly-conserved 
stalk to be exposed. Controlling the orientation altered the ability of our vaccines to induce 
protective levels of stalk-specific antibodies. These results suggest that the accessibility of 
the HA stalk is a factor in the limited generation of stalk-specific antibodies via traditional 
vaccines or natural infection. Furthermore, simply by controlling the orientation of HA to 
a nanoscale scaffold, we have redirected the immune response to the conserved stalk 
epitope, thus showing the potential of this scaffold to be used as a universal influenza 
vaccine that would elicit broadly active antibodies across several strains of influenza. 
2.5 Future work 
The initial viral challenge data looks very promising. Similar vaccinations will be 
performed using scaffolds functionalized with HA (purified by both affinity 
chromatography and SEC) and will be followed by a fully heterologous viral challenge 
with an H5/N1 virus. Additionally, the serum will be analyzed specifically to measure the 
response that was achieved to the HA head and stalk regions of the protein. The serum will 
be tested against rescued influenza viruses that express chimeric HA proteins to 
differentiate the responses. Additionally, there is continued work going forward to generate 
similar particles based on a group 2 H3 HA protein. The broadly neutralizing activity will 
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likely not be cross group reactive, so a bivalent vaccine will likely be necessary to produce 





CHAPTER 3. STRAIN SPECIFIC IMMUNOGENIC RESPONSES 
TO RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN 
DEPEND ON SITE Ø SPECIFICITY 
3.1  Introduction 
 Respiratory Syncytial Virus (RSV) is the leading cause of bronchiolitis and 
pneumonia in infants71. Synagis© is the only licensed treatment available. It is a 
prophylactic antibody that requires monthly injections, thus limiting its use to extremely 
high-risk patient groups and making the widespread adoption of such a treatment unlikely.  
Given these statistics it is alarming that there is still no licensed vaccine available. This is 
due in part to the propensity of anti-RSV antibodies to lead to antibody-associated disease 
enhancement when the antibodies generated in response to the vaccines does not achieve 
the necessary titer or specificity for protection72,73. Efforts to boost titer to circumvent ADE 
are challenging because one of the main target groups for immunization is pregnant 
women, which necessitates developing a vaccine without using an adjuvant. Still, recent 
developments in understanding the immune response to RSV and protein engineering 
developments have given new insights and tools to develop the next generation of potential 
RSV vaccines.  
 The two major antigens on RSV are the surface glycoproteins F (fusion protein) 
and G (attachment protein). Of the two, the F protein is more conserved from strain to 
strain, and thus is the focus of many vaccine development efforts74,75. The F protein exists 
in two conformations on the surface of the virion, the metastable prefusion conformation 




Figure 14. Crystal Structures of RSVF. RSFV prefusion and postfusion conformations from (refs). 
The dark purple and dark blue surfaces are conserved on both conformations, while the pink and 
light blue regions are specific to each conformer. The epitopes for several antibodies are also 
pointed out. D25, mpe8, and 58c5 bind only to the prefusion protein, Motivizumab and 101F bind 
to both conformers. 
D25






shift from preF to postF. Only 50% of the solvent exposed protein surface area is conserved 
between the two conformers76. Recently, McClellan et al. engineered an RSV F protein 
that is stable in the prefusion conformation77. This allowed Ngwuta et al to determine that 
over 90% of neutralizing antibodies to RSV found in human sera are specific to preF, 
whereas only 10% are specific to postF76. Interestingly, over 45% of these neutralizing 
antibodies are specific for a single antigenic site Ø that is found at the membrane distal 
region of preF. Thus, new attempts to develop an RSV vaccine are focused on generating 
antibodies to preF and specifically to antigenic site Ø. 
 Our work in this area is twofold. First, we hypothesize that we can increase the 
immunogenicity of RSV preF to generate high titers of antibodies that will neutralize RSV. 
Secondly we are interested in probing the importance and efficacy of antigenic site Ø. 
Antigenic site Ø is the most variable region of the F protein78. Excluding site Ø, RSV F 
protein has 94% homology across strains. Within protein F, the homology is only 77%78. 
Our hypothesis is that antibodies to site Ø are less likely to bind to and neutralize disparate 
strains of RSV than are other prefusion-specific antibodies that bind to other regions on 
preF. We have generated vaccine constructs that present two versions of stable preF: the 
wild-type protein, and a mutant protein that has 3 inserted glycosylation sites within 
antigenic site Ø (glycan KO)76. This mutant inhibits antibody binding, to site Ø and we 
hypothesize that it will also inhibit the generation of antibodies against site Ø. These 
vaccine constructs will allow us to test the broadly neutralizing activity of site Ø antibodies 
generated from a preF vaccine construct.  
3.2 Materials and methods 
3.2.1 Expression of Antibodies and RSVF 
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DNA coding for Sc-tm RSVF79 and the variable domains of anti-RSVF antibodies 
was optimized for human expression and synthesized by Genscript. RSFV DNA was 
cloned into pcDNA3.1 between NcoI and XhoI with a leader peptide to direct the protein 
into the solution media. Site directed mutagenesis was performed as needed to generate 
mutant proteins using the Q5 SDM kit (NEB). Antibody DNA was cloned into the TGEX 
vector series per the manufacturer’s protocol (company name). All proteins were expressed 
in HEK293F cells using the Expifectamine transfection kit. Strep-tagged (streptag II) 
RSVF was purified by affinity purification on a GE HiStrep column followed by SEC on 
a GE Superdex 200Increase 10/300 column. Antibodies were purified over protein A resin.  
3.2.2 ELISA analysis 
RSVF proteins were coated overnight at 4oC, 0.1 µg/well in 50 mM carbonate 
buffer, pH 9.6 on Nunc Maxisorp plates. Wells were blocked for 1 hr at RT with 5% BSA 
in PBS-tween, washed, and primary antibodies were added at appropriate dilutions in 1% 
BSA in PBS-tween for 1 hr. HRP-linked secondary antibodies were used for detection.  
3.2.3 Vaccine construct assembly 
RSVF proteins were expressed as described79 with a C-terminal spytag peptide 
incorporated. Azide-containing Spycatcher protein (Az-SpCat) was expressed in E. coli 
and purified using IMAC. After purification, Az-SpCat was reacted in excess to a 4 arm 
20 kDa PEG molecule. PEGs with 3-4 Az-SpCats attached were purified by SEC and 
concentrated. Excess RSVF was added and allowed to react overnight at 4oC. Final vaccine 
constructs were purified by SEC before being used in immunizations.  
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3.2.4 Immunization 
Immunizations were carried out by ProSci, Inc. In short, 2 µg RSVF protein 
adjuvanted with Addavax (Invivogen) was injected subcutaneously into mice at days 0, 14, 
and 28 and mice were terminally bled on day 35. Final injection volumes were 80 µl per 
injection. Immediately prior to each injection, serum was collected for analysis. Each 
vaccine group was tested on n=5 BALB/C mice, 6-8 weeks old.  
3.2.5 Serum analysis 
First test bleed serum will be pooled from each group and all serum samples will be 
split in two, have being left and half being depleted of non-site Ø antibodies as described 
previously76. Resulting control and depleted sera will be tested for ELISA titer to RSFV 
glycan KO and the RSVF B Site Ø mutant proteins. Further serum analysis for titer and 
neutralization efficacy against full RSV viral strains will be performed in the labs of our 
collaborator according to previously described methods. 
3.3 Results 
3.3.1 Expression of RSVF and Glycan KO proteins 
RSVF proteins were expressed through transient transfections into mammalian 
HEK 293F cells. Untagged proteins were purified from the cell supernatant by cation 
exchange x`chromatography followed by SEC. Streptagged proteins were purified by 
replacing the cation exchange step with a sreptactin column. Figure 15 shows the 
expression of both the wild type and glycan knock out (glycan KO) versions of RSVF. 
There is a slight MW change seen in SDS-PAGE indicating the glycosylations successfully  
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Figure 15. Expression of RSV preF. (A) SDS-PAGE of purified RSVF proteins, both the wild-type 
prefusion RSVF (wt RSVF) and the Site Ø glycan knockout mutant. Reprinted with permission 
from MacMillen Publishers, Ltd. (B) SEC-MALS of wt RSVF showing the assembly of the trimer. 
(C) Modeled image of glycan mutations added to Site Ø to block antibody binding, from Ngwuta, 
et al. 201576, reprinted with permission. (D) The glycan mutant showed a shift in MW (See panel 

































































occurred. SEC-MALS was used to verify the presence of the trimeric species. Figure 15C 
shows a model of the glycosylated protein showing how site Ø is blocked by the attached 
glycans. Lastly, the glycans make a steric difference on the surface of the trimeric protein 
as seen in the SEC chromatograms that the glycan KO elutes before the wtRSVF.  
3.3.2 Expression of antibodies against RSVF 
 In order to probe the correct folding of the expressed RSVF, as well as analyse the 
serum responses to the vaccines developed, we expressed several antibodies to RSVF. The 
antibody epitopes are shown in Figure 14. The antibodies were purified over protein A 
resin, and an SDS-PAGE gel of the antibodies is shown in Figure 16 and were used in 
further ELISAs for testing RSVF.  
3.3.3 ELISA analysis of RSVF proteins 
 RSVF proteins were coated on ELISA plates and probed for binding to each of the 
expressed antibodies. wtRSVF bound to all antibodies showing that it is correctly folded 
(Figure 17). Glycan KO RSVF bound to all antibodies other than D25, showing that is it 
both correctly folded and that it sterically inhibits antibodies from binding to site Ø. 
Additionally, added purification and conjugation peptide tags to the C-terminus of the 
protein did not alter antibody binding.  
3.3.4 Expression and analysis of an RSVF B site Ø protein 
As was mentioned earlier, site Ø is the most variable region of RSVF. Figure 18 shows the 
compared sequences of RSVF A2 and an RSVF B strain within the site Ø epitope. Six 
residues are different between the two strains, and of them, three residues directly contact 




Figure 16. RSVF antibody expressions. SDS-PAGE of antibodies expressed to bind to RSVF. The 










Figure 17. ELISA of RSVF proteins. Expressed RSVF proteins were coated and probed with RSVF 
antibodies. Blue bars: wtRSVF binding. Red bars: glycan KO binding. Glycan KO binds to all 
























Figure 18. Variability within Site Ø. The sequences of the Site Ø epitope in RSV/A2 and RSV/B are 
compared. Red residues are in the RSV/B sequence differ from those in RSV/A2, and underlined 





Site Ø Residues 
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mutated to the RSVF B strain sequence. The expressed B site Ø protein bound in ELISA 
to Motivizumab (Figure 19; all other non-site Ø antibodies bound B site Ø RSVF, data not 
shown). However, the protein showed a markedly lower affinity for site Ø antibodies D25 
and AM22 than the wild-type protein. This result encouraged us to hypothesize that 
generated site Ø-directed antibodies in a typical antibody response will not be as effective 
at cross strain protection as those generated specifically against epitopes other than site Ø.  
3.3.1 RSVF vaccine design and assembly 
RSVF vaccines were designed based on the spycatcher-spytag conjugation strategy67. 
Illustrated in Figure 20, the spycatcher protein forms an isopeptide bond with the spytag 
peptide that can be attached to a protein. We conjugated spycatcher to a 4-arm PEG 
molecule via a dibenzylcyclooctyne (DBCO)-Azide reaction. The spycatcher proteins were 
expressed with the mutation T56pAzF, to add an aizide moiety on the opposite site of the 
reactive lysine. The PEG-spycatcher scaffolds were then mixed with RSVF and the fully 
conjugated vaccine was purified by SEC. We were able to purify a mixture of 3 and 4 
spycatchers per PEG molecule and thus the final vaccine construct was comprised of 
molecules with 3-4 RSVF trimers on them. We generated vaccines using wtRSVF and 
Glycan KO RSVF, as well as a control vaccine composed of the scaffold alone.  
3.3.2 Immunizations and Serum analysis 
Immunizations are currently underway by ProSci, Inc. We will assess the binding and 
neutralization activity of both the full serum samples and serum that has been depleted of 
all anti-RSVF antibodies other than those to site Ø. The serum depletion test has been 
reported previously using the Glycan KO RSVF to pull down all non-site Ø-binding  
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Figure 19. RSVF-B Site Ø mutations block Site Ø antibodies. RSVF-B Site Ø was probed by three 
















































Figure 20. RSVF vaccine design. (A) Vaccine scaffolds are based on the spycatcher-spytag system 
developed by Brune et al67 (reprinted with permission). The spycatcher protein reacts with a spytag 
peptide to form and isopeptide bond. Adapted with permission from Brune et al. (B) The core of 
the vaccine is a DBCO activated 4-arm PEG molecule that is conjugated to spycatcher via an 
inserted pAzF residue opposite of the reactive face of the protein. (C) Final vaccine assembly was 
performed by mixing Spycatcher-PEG with spytagged RSVF (spytag represented in blue). The 









Figure 21. Protein Gel of RSVF vaccine assembly. Lanes: M – marker; 1 – Spycatcher+4-arm-PEG 
purified to a mixture of trimeric and tetrameric spycatcher protein; 2 – pure wtRSVF, 3 – purified 
wtRSVF vaccine with activated scaffold present, the ~60 kDa band results from the RSVF trimer 
disassembling under SDS-PAGE and is not soluble RSVF; 4 – pure glycan knockout RSFV; 5 – 
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antibodies. We have done initial experiments to verify that the serum depletion assay will 
work. Firstly, we combined site Ø binding antibodies or non-site Ø binding antibodies to 
create a mock serum sample. These antibody mixtures were then depleted with glycan KO 
RSVF and assayed for residual binding (Figure 22A). The site Ø antibodies retained almost 
all of their binding, showing that site Ø antibodies will be retained in the depleted serum. 
Conversely, over 80% of the binding from non-site Ø antibodies was removed. To further 
verify our ability to perform a serum depletion test with immunized mouse serum, we 
depleted serum with reactivity towards GFP with soluble GFP in the same manner (Figure 
22B). The serum that was not depleted or passed over a mock protein retained binding, 
whereas approximately 75% of the binding from antibodies was removed by the depletion 
step. These results make us confident that the serum depletion experiment with RSVF-
reactive serum will work as well. We will initially test the ability of the serum generated 
to bind to the B site Ø RSVF mutant we have expressed. If the site Ø antibodies generated 
show decreased binding to the RSVF/B sequence, we will then work with our collaborators 
at Emory University to assay for titer and neutralization activity against a library of RSV 
strains.  
3.1 Discussion 
The generation of an effective RSVF vaccine would be an effective way to decrease the 
disease burden that RSV causes, especially in newborn infants. Our work has been meant 
to uncover the potential ramifications of focusing on generating an immune response 
specifically to site Ø. Antibodies that are less effective on diverse strains of the virus could 
lead to further antigenic drift or antibody mediated disease enhancement. By doing this 




Figure 22. Serum depletion. (A) Two pools of antibodies that bind to RSVF were made; one of non-
site 0 binders (101F, mpe8, Motivizumab) and one of Site 0 binders (D25 and AM22). Antibodies 
were depleted from the samples by exposing to site 0 KO RSVF and pulled down by magnetic 
beads. Over 80% of the non-site 0 antibodies were pulled down, while the Site 0 antibodies 
remained in solution. (B) Mouse serum that was reactive to GFP was diluted and exposed to GFP 
and pulled down with magnetic beads. Again, depleting the serum with GFP resulted in close to 































3.2 Future work 
The vaccine scaffold used here was desirable because it allowed for covalent attachment 
of RSVF to the scaffolding molecule. Future work in this vaccine design space will be 
geared toward assessing the importance of the vaccine scaffold architecture in generating 
broadly neutralizing antibodies. Further, the insertion site of the spytag sequence is being 




CHAPTER 4. NANOPATTERNING SOLUBLE PROTEIN 
ANTIGENS TO GUIDE IMMUNE RECOGNITION TO DESIRED 
EPITOPES  
4.1 Introduction 
Vaccination remains one of the most effective methods to prevent disease. However, 
due to variations in pathogenic proteins and antigenic drift, several pathogens can evade 
the immune responses elicited by potential vaccines. It is becoming more and more clear 
that generating immune responses to specific regions of proteins that are highly conserved 
or show higher neutralization potential can potential circumvent a pathogen’s route of 
immune evasion76,80–83. Consequentially, there exists a need to develop methods to refocus 
the immune response toward these desirable epitopes. 
Glycosylation is used in nature to alter the immune response to antigenic proteins. 
This is well documented for both simian immunodeficiency virus and human 
immunodeficiency virus that have glycosylation patterns that shield neutralizing epitopes 
from the immune system80,81. Efforts to mimic this natural phenomenon include adding and 
removing glycosylation sites or changing the expression system to increase or reduce the 
size of glycan modifications82,84. Recently, Du et al. used site specific glycosylation to map 
epitopes on the MERS corona virus that are important for generating neutralizing 
antibodies83. However, there are limitations to using glycosylation for modulating protein 
antigens. First, this posttranslational modification is often vital for proper folding of 
proteins. Second, glycans themselves can become part of neutralizing epitopes85. Finally, 
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glycosylation is a blunt tool that does not allow for tailoring the structure of the glycans in 
a site-specific manner. 
We therefore have developed a method for nanopatterning protein antigens that 
combines site-specific mutations with biochemical conjugation to shield desired protein 
epitopes. In short, non-cannonical amino acids can be inserted near a desired epitope to 
shield and then the protein can be directly functionalized with molecules such as PEG to 
shield the epitope. We have used this approach on a model protein, GFP, to illustrate the 
ability to refocus the immune response to specific epitopes. 
4.2 Materials and methods 
4.2.1 Protein expression and purification 
DNA coding for superfolder-green fluorescent protein (sfGFP, PBD ID: 2B3P) and 
spycatcher (PDB ID: 4MLI) was optimized for expression in E. coli and synthesized by 
Genscript, Inc. (Carlsbad, CA) with a c-terminal hexahistidine tag. Spycatcher had an 
additional N-terminal streptag. The coding region was then cloned into a modified pet28b 
vector between the NdeI and XhoI cut sites with the n-terminal tag removed. Site-directed 
mutagenesis was performed using the Q5-SDM kit (New England Biolabs, Ipswich, MA). 
Primers were designed using the NEBasechanger tool. For expression of proteins not 
containing the amber codon, pet28b vectors were transformed in BL21(DE3) E. coli and 
grown at 37oC in 2xYT media with 50 µg/ml kanamycin. Expression was induced by the 
addition of 1 mM IPTG at OD=0.5-0.9. After induction, the temperature was lowered to 
30oC and expression continued overnight. Pet-28b plasmids for expressing uAA containing 
proteins were co-transformed with pEvol-pAcFRS.2.t1 (a gift from Farren Isaacs, Addgene 
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plasmid #73544) to add the machinery to insert the unnatural amino acid (uAA) p-
azidophenylalanine (p-AzF) in response to the amber codon. Cells were grown in 2xYT 
media supplemented with 50 µg/ml kanamycin and 50 µg/ml chloramphenicol. At 
OD=0.5-0.8, 0.02% L-arabinose and 1 mM p-AzF were added to induce the production of 
the uAA machinery, and at OD=1.3-1.5, 1 mM IPTG was added, and expression continued 
at 30oC overnight. After expression, cells were pelleted by centrifugation at 4000xg for 30 
min. Cell pellets were suspended in buffer A (50 mM Tris, 500 mM NaCl, 50 mM 
imidazole, pH 8) containing 1 mg/ml lysozyme and a protease inhibitor cocktail (S8830, 
Sigma Aldrich, St Louis, MO). After 30 min incubation at 4oC, 0.1% deoxycholate was 
added and cells were lysed by sonication until no longer viscous. Cell lysates were clarified 
by centrifugation at 30,000 x g for 30 min at 4oC. Clarified lysates were filtered through a 
0.45 µm filter and mixed with Nickel-NTA resin (Pierce). After a 2-hour incubation at 
20oC, the slurry was added to a drip column and allowed to gravity drain. The resin was 
washed with 10 column volumes (CV) of buffer A, followed by 10 CV of buffer A with 
100 mM imidazole. Purified proteins were eluted with 500 mM imidazole in buffer A. 
Eluted GFP proteins were buffer exchanged into PBS by spin filtering through a 10 kDa 
MWCO filter and concentrated prior to storage in the dark at 4oC. Eluted spycatcher 
proteins were then loaded onto a streptactin column (GE Healthcare), washed with 20 CV 
binding buffer (100 mM Tris, 150 mM NaCl, 1 mM EDTA) and eluted with 2.5 mM 
desthiobiotin in binding buffer. Purified spycatcher was buffer exchanged and concentrated 
through a 3 kDa MWCO filter and stored at 4oC until further use. 
4.2.2 PEGylation and purification 
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GFP double mutant contained p-AzF at residues 131 and 209. Gfp triple mutant 
contained p-AzF at residues 34, 109, and 200. SPycatcher-Az contained the mutation 
T56Az. p-AzF containing proteins were mixed at >10 mg/ml with excess (5-10 molar 
excess) 2 kDa mPEG-DBCO (Nanocs, New York, NY) and left to react overnight at room 
temperature or at 4oC for >48 hrs. PEGylated GFPs were purified by native gel 
electrophoresis. After running, bands were excised and protein was eluted by placing the 
excised band in PBS and letting it rock at 4oC overnight. Soluble protein was then 
concentrated as before. Spycatcher-PEG was purified by SEC on a GE Superdex 200 
prepgrade 16-60 column, eluted in PBS. All proteins were confirmed to have PEG by SDS-
PAGE and MALDI-TOF mass spectrometry. Final Pegylated proteins were isolated in pBS 
by elution through a GE Superdex 75 10/300 SEC column. 
4.2.3 Purification of protein tagged GFP 
Spycatcher-PEG was mixed with excess spytagGFP containing an inserted spytag 
and spacer (GSGGSGGSGGSGAHIVMVDAYKPTKGSGGSG) after residue 52. After 
overnight incubation at 4oC all spycatcher PEG was consumed and the mixture was passed 
over a streptactin column to remove unreacted spytagGFP. This protein-conjugate was 
finally purified by SEC on a GE Superdex 75 10/300 column. 
4.2.4 Immunizations 
Immunizations of GFP related proteins were carried out by ProSci, Inc. (Poway, 
CA). In brief, protein antigens were diluted to 75 µg/ml prior to sending to ProSci. On days 
0,14, and 28, 3 µg of antigen were injected adjuvanted with Addavax. On day 35 mice were 
bled and serum was kept for analysis. 
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4.2.5 Serum analysis 
Mouse serum to GFP will be assessed for endpoint titer against wtGFP. and other GFP 
mutant proteins to assess site specific-reactivity of the antibodies. In short, GFP proteins 
will be captured onto streptavidin coated ELISA plates via a site-specific biotinylation with 
DBCO-Biotin. 
4.3 Results 
4.3.1 Selecting PEG conjugation parameters 
We used PEG as an initial test to validate our ability to shield protein epitopes from 
the immune system and redirect the immune response. We first identified epitopes on GFP 
that had been previously used as immunogens for commercially available antibodies. 
Figure 23 shows the epitopes on GFP that were identified. For proof of principle, we chose 
epitope 1 as the region that we would try to either block or direct the immune response 
toward. For blocking, the selection of residues was based on solvent accessibility of the 
sidechain and proximity to the epitope. To ensure that the antibody blocking effects seen 
were directly related to the shielding effects and not to the unnatural amino acid 
incorporation, we selected residues to mutate that were near but not within the specified 
epitope. For directing the immune response toward the epitope, we selected solvent 
accessible residues distant from the epitope that were evenly spaced to allow shielding of 
the non-epitope surface of the protein. 
The size of PEG was selected based on the root-mean-square (RMS) end-to-end distance. 




Figure 23. Selecting mutants for site specific bioconjugation. Mutant 1 was designed to shield the 
highlighted epitope (cyan). Residues K131 and K209 (red) were mutated to p-AzF and conjugated 
to 2 kDa mPEG-DBCO. Mutant 2 was designed to guide the immune response toward the 
highlighted epitope by shielding distant regions with PEG (E34pAzF, R109pAzF, and Y200pAzF 
in yellow). Spytag GFP also blocks the highlighted epitope with an inserted Spytag peptide 










distance of 4.2 nm86 and thus can feasibly shield epitopes without covering the entire 
surface of the protein. 
4.3.2 Expression, purification, and PEGylation of proteins 
Amber stop codons were inserted into GFP at the desired codons, and the protein was co 
expressed in E coli with plasmid pEVOL-pAzRS2.t187 for the incorporation of p-
azidophenylalanine (p-AzF). The purified full length protein was then reacted with excess 
mPEG-DBCO. The small length of PEG made purification of the final PEGylated protein 
by chromatography difficult. Instead, we chose to use native polyacrylamide gel 
electrophoresis (PAGE) to separate differently PEGylated proteins on the basis of the 
altered m/z ratio. Figure 24 shows an example image of a PEGylated reaction mixture after 
separation by native PAGE. After excising the band, we were able to obtain fully 
PEGylated proteins to be used as immunogens. Figure 25 shows an SDS gel showing that 
both non-PEGylated and PEGylated proteins were purified to homogeneity before 
proceeding with immunizations. The addition of PEG was verified by MALDI-TOF mass 
spectrometry, and an example result is depicted in Figures 26-27. The MW of non-
pegylated GFP is close to 27.7 kDa, and after the addition of 2 or 3 2kDa PEG molecules, 
the mass shifts correspondingly. 
4.3.3 Elisa analysis of protein antigens 
Purified proteins were then coated on ELISA plates and probed with antibodies 
binding to the specified epitopes (Figure 28). Non-PEGylated wild type and mutant 
proteins bound to all antibodies. As shown in Figure 28, the doubly PEGylated mutant 




Figure 24. Native-PAGE Separation of PEGylated GFP. PEGylated GFPs were separated by 
Native-PAGE. The indicated bands, corresponding to fully PEGylated GFP were excised and 
processed as GFP antigens.  




Figure 25. SDS-PAGE of GFP antigens. Lanes: (M) Marker, (1) wild type GFP, (2) Mutant 1 GFP 
– K131pAzF+K209pAzF, (3) PEGylated Mutant 1 GFP, (4) Mutant 2 GFP – 
E34pAzF+R134pAzF+Y200pAzF, (5) PEGylated Mutant 2 GFP, (6) GFP-PEGylated Spycatcher 




Figure 26. MALDI-TOF spectra of non-PEGylated GFP antigens. wtGFP, Mut1 and Mut2 were 
analyzed by MALDI-TOF to confirm  insertion of the pAzF residues. The increase in MW of the 

































































































































Figure 27. MALDI-TOF spectra of PEGylated GFP antigens. PEGylated GFP mutants after 
purification were submitted for mass psec analysiss. The broad peak coris a result of the 
polydispersity of the PEG molecules, but the large 2 kDa shiftseen between PEGylated mutant 2 
(MW: ~32kDa) and PEgylated mutant 2 (MW ~34.4 kDa) indicates that the PEGylation was 
successful. The lower MW shoulder is a result of trace amounts of n-1 PEGylated product not fully 


















































Figure 28. GFP antigens selectively bind to antibodies. (A) GFP antigens were coated on ELISA 
plates and detected with antibody GSN149 that binds to the cyan highlighted epitope depicted in 
Figure 23. The PEGylated proteins marginally inhibit antibody binding, whereas the Spytag GFP 
largely inhibits antibody binding. (B) GFP antigens were also detected with an N-terminal binding 
antibody that binds to a distal region of the protein from the GSN149 binding site. The PEGylated 








































triple PEGylated protein does not block antibody 1, but does block antibodies 2 and 3. 
These ELISA results showed us that the PEGylated proteins did have the potential to 
alternatively block and direct an immunological antibody response to epitope 1. 
4.3.4 Immunization and serum analysis 
Serum from each mouse was collected prior to each injection, and one week 
following the final injection. Data is still being collected but we have analysed the serum 
from wtGFP and Spytag GFP for titer against wtGFP. Figure 29 shows that the overall 
antibody titer to wtGFP is the statistically the same after immunizations with wtGFP or 
spytag GFP. The antibody response to spycatcher is significantly lower than to wfGFP. 
This is likely caused by the direct PEGylation of the spycatcher protein, thus lowering its 
immunogenicity. As the serum returns from immunizations we will test the reactivity to 
wtGFP as well as to site-specifically immobilized GFP. The results from these tests will 
enable us to verify that nanopatterning does enable us to direct the immune response. 
4.1 Discussion 
We have developed an approach to nanopattern protein antigens to shield specific 
epitopes from the immune response. This approach is orthogonal to glycosylation and as 
such, mitigates the inherent challenge to epitope shielding by glycosylation. The 
nanopatterning method allows for site specific conjugation to any protein. We have shown 
this by incorporating unnatural amino acids for direct bioconjugation to shielding 
molecules and by peptide insertion to allow for enzyme mediated conjugation (in the case 
of the spycatcher-spytag approach). This method could potentially be useful for various  
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Figure 29. Wild Type and Spycatcher-GFP immunization results. (A) Immunization schedule. (B) 
Serum endpoint titers to Wild-type GFP, using wild-type GFP (orange circles), and spycatcher 
GFP (blue tirangles) as antigens. (C) Serum enpoint titers against spycatcher, same legend as in 
(B). 
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vaccine targets where a guided immune response would be beneficial (such as to the 
stalk domain of HA).  
4.2 Future work 
We are currently looking at nanopatterning other pathogenic proteins to direct the 
immune response to key epitopes (influenza HA, and Zika DIII). Additionally, we have 
not studied the importance of the specific molecule that is used to shield the protein epitope. 
This could be done first in ELISA by testing such things as branched PEGs, glycans, or 
dendrimers. The insertion of unnatural amino acids or peptides for conjugation has been 
done thus far by trial and error. Optimizing the location of mutations and the length of 







CHAPTER 5. INDUCING CELLULAR SIGNALING THROUGH 
MULTIVALENCY BY CONTROLLING LIGAND DISPLAY ON 
POLYMER AND POLYPEPTIDE SCAFFOLDS  
5.1 Introduction 
 It has been established herein that multivalent molecules can induce and proliferate 
cell-signaling pathways in diverse cells26-35. It is clear from the literature that different 
scaffolds and conjugation densities of ligands on those scaffolds can drastically change the 
effectiveness of a multivalent molecule to induce signaling31,32,88. Still, because most 
multivalent molecules are based on polymer backbones that are randomly activated, it has 
been difficult to test how the parameters of ligand valency and inter-ligand spacing 
modulate the effectiveness of these molecules88. We have developed a polypeptide-based 
scaffold that allows for precise control of both valency and spacing to enable the study of 
these two parameters independently. We have used these scaffolds to test how the spacing 
of Ephrin B4 peptides changes signaling potential and have developed a method to test 
these same parameters within the Wnt signaling cascade.  
Wnt signaling is vital for embryonic development, can induce stem cell signaling, 
and is implicated in cancer growth89–91. It is interesting among signaling pathways because 
of its use of two surface receptors. As shown in Figure 33, soluble Wnt binds to both LRP6 
and Frizzled (FZD) and the induced co-clustering of the receptors induces downstream 
effects92. It has also been shown that clustering LRP6 alone can either initiate or enhance 
Wnt signaling89,93,94. Furthermore, Wnt is an inherently complex protein with several 
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posttranslational modifications, including 10 disulfide bonds and a lipid modification. Just 
recently, Janda et al. developed a synthetic Wnt molecule based on protein design strategies 
and natural LRP6 ligands95. Even with this development, the fact that LRP6 clustering 
plays a role in signal strength leads us to hypothesize that higher valency molecules may 
have therapeutic advantages. We have therefore developed a platform to test multivalent 
Wnt agonists that can enhance or induce Wnt signaling. 
5.2 Materials and methods 
5.2.1 Generation of polypeptide scaffolds 
DNA encoding base scaffolds [(SE)10K]10SE10H10 and [(SE)30K]10SE30H10 were E. 
coli optimized and synthesized by Gensript. Shorter constructs were them assembled by 
deleting segments of the DNA by site-directed mutagenesis. Coding DNA was cloned into 
pet28b between Nde1 and XhoI. Protein scaffolds were expressed in BL21(DE3). After 
expression, cells were lysed by sonication, and the cell lysate was heated to 70oC for 30 
min and then clarified by centrifugation. Proteins were purified from clarified lysate using 
Ni-NTA resin via standard protocols. 
5.2.2 Activating polypeptide scaffolds 
Purified scaffold proteins were first activated by adding an NHS-malemide 
crosslinker, SMCC in excess to the number of lysines on the scaffold. After desalting, 
activated backbones were added to excess peptides with free sulfhydyl groups. Fully 
activated scaffolds were purified from the reaction mixture by buffer exchange through a 
10 kDa MWCO spin filter.  
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5.2.3 Stem cell signalling tests 
Stem cell signalling tests were performed by our collaborators at UC Berkeley. In 
short, adult neural stems cells were grown under standard conditions. Polypeptide scaffolds 
were activated with peptides from Ephrin-B4 and conjugated multivalent molecules were 
added to cell culture media. Cells were then stained for nuclei (DAPI) and for βIII-tubulin 
as a differentiated neural cell marker, and imaged using confocal microscopy. The 
percentage of cells positively staining for βIII-tubulin was reported. 
5.2.4 Antibody and Fab expression and purification 
The variable regions of LRP6- and Fzd-binding antibodies were cloned into the 
TGEX vector series for expression as full length antibodies and Fab fragments. Proteins 
were expressed in HEL293F cells and purified by affinity chromatography on protein A or 
protein L resins.   
5.2.5 Wnt responsive luciferase reporter assay 
HEK293T cells were stably transfected with a 7TFP reporter plasmid that expresses 
luciferase under the control of β-catenin. 7TFP was a gift from Roel Nusse (Addgene 
plasmid # 24308)96 . Cells were transiently transfected with Wnt1 or Wnt3a and after 24 
hours, were replated at 50000 cells/well of a 96-well plate. At this point, antibodies or 
multivalent conjugates were added, and after 16 hrs, cells were lysed and the luciferase 
activity was measured. 
5.3 Results 
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5.3.1 Expression and characterization of protein-based multivalent scaffolds 
Polypeptide-based scaffolds were expressed in E coli and purified over Ni-NTA. The high 
solubility of the scaffolds allows for a heated pre-treatment of cellular lysates to clear host 
cell proteins. The expression yield was low, from 0.2-5 mg/L culture, necessitating the 
pretreatment step to enhance protein capture on the Ni-NTA resin. Figure 30 shows three 
purified scaffolds that have the same inter-reactive residue spacing and differ only in 
valency. Each of the scaffolds were tested in circular dichroism to confirm a largely random 
coil structure. Regardless of scaffold length, all of these protein-based scaffolds exist in 
primarily random coil structures, making them behave similar to a polymer scaffold in 
solution. 
5.3.1 Activation with Ephrin-B4 peptide and stem cell differentiation. 
Scaffolds were then activated with NHS-malemide (SMCC) followed by a 2 kDa 
peptide from Ephrin B4. The percentage of cells that differentiated into full neurons was 
tracked by the expression of βIII-tubulin. Interestingly, the scaffold with the longer spacing 
between ligands (Figure 32) showed higher cell signaling than the shorter inter-ligand 
spacing. We hypothesize this is because the longer spacing better matches the distance 
spanned between clustered Eph receptors.  
5.3.2 Wnt Signaling assay 
We have also developed a method to test signaling by both Wnt1 and Wnt3a. 
HEK293T cells have been stably transfected with a reporter plasmid carrying a luciferase 




Figure 30. Polypeptide scaffolds for multivalent display. Polypeptide scaffolds are built of repeated 
blocks of SE repeats and a K residue. Shown are two such scaffolds. After reacting with a 
crosslinker, NHS-Malemide, the scaffolds are reactive to thiols and can be functionalized with 
protein or peptide ligands. In this depiction, the two scaffolds have been activated with an Eprin-









Figure 31. Expression and characterization of polypeptide scaffolds. (A) Purified [(SE)30K]nSE30H10 
proteins were run on SDS-PAGE after purification. By changing the valency, n, the size of the 
scaffold changes while keeping the linear spacing between linkable residues the same. (B) Each of 
the three scaffolds purified was analyzed by circular dichroism to verify the secondary structure. 


































Figure 32. Induced Ephrin-B4 signaling using polypeptide scaffolds. (A) Percent of cells staining 
positively for βIII-tubulin, a neural cell marker in response to treatment with Ephrin signaling 
molecules. Cells treated with antibody or [(SE)10K]10(SE)10H10 are not as effective as cells treated 
with [(SE)30K]10(SE)30H10. (B) Representative confocal micrographs of cells activated with 








genes for either Wnt1 or Wnt3a are then transiently transfected into cells and after 24 
hoursthe cells are plated in the final assay and incubated for 16 hrs. A time course 
experiment (Figure 34) has shown us that 16 hours post-plating the luciferase activity is 
well within the dynamic range of the assay will allow us to see both up and down regulation 
of Wnt signaling.  
5.3.1 Antibody mediated signal inhibition 
 We first tested whether the expressed Fzd binding antibody would compete for Wnt 
binding and signaling on HEK293T cells. Indeed, for both isoforms of Wnt, anti-Fzd 
antibody blocks Wnt signaling, where as a control antibody has no effect (Figure 35). This 
result confirms that we have antibodies that bind to Fzd and can be used in multivalent 
constructs. 
5.4 Discussion 
We have shown that by using a polypeptide scaffold we can directly control the 
ligand spacing and valency in a multivalent conjugate. These scaffolds can be useful tools 
in studying diverse signaling pathways, and have potential use as therapeutic molecules. 
The design of the SE backbone provides both flexibility and solubility allowing even 
hydrophobic ligands to be attached to the scaffolds. Further, having the scaffolds designed 
with only the reactive residue coded genetically can allow for one to quickly screen valency 
and ligand spacing at will for any ligand/signaling pathway of choice. We have also 
developed an assay to test Wnt signaling modulation in response to multivalent molecules. 




Figure 33. Mechanism of Wnt signaling92. Wnt binds the extracellular domains of Fzd and LRP5/6. 
Creation of a signalsome frees β-catenin to enter into the nucleus and turn on downstream genes. 





Figure 34. Wnt signaling assay development. Schematic of Wnt signaling assay including a time 
course experiment verify that after cell lysis, we are detecting luciferase activity in a dynamic 
ranges that will allow for both upregulation and down regulation to be seen. 
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Figure 35. Anti-Fzd Ab inhibits Wnt signaling. Soluble monoclonal antibodies were added to cells 
after transfection with wnt expressing plasmids. Anti-CCR5 showed no inhibition of signaling, 
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receptors in Wnt signaling may necessitate more sophisticated scaffolds to probe 
the importance of both receptors and the make-up of potent signalosomes. 
5.1 Future work 
Going forward, we will be expressing LRP6-binding antibodies and Fabs and using 
them in conjunction with anti-FZD antibodies to generate multivalent activators of Wnt 
signaling. We are also working to generate a larger library of polypeptide scaffolds that 




CHAPTER 6. CONCLUSION 
We have applied multivalency to vaccine design and stem cell signaling. By 
controlling the presentation of antigens, both on scaffolds and by nanopatterning, we have 
been able to alter the cellular responses to the proteins. We have seen, firstly, that reversing 
the orientation of HA on the surface of a VLP-based vaccine can redirect the immune 
response toward the conserved stalk domain of HA. These stalk-reactive antibodies have 
the potential to be broadly active against multiple strains of influenza. We are also probing 
the importance of site Ø in generating broadly neutralizing antibodies against RSV. 
Additionally, we have developed ways to nanopattern protein antigens with the potential 
to redirect the immune response toward desirable epitopes. Lastly, we have developed 
scaffolds that can present well-defined multivalent ligands to induce cell signaling 
pathways including the Eph-ephrin and Wnt signaling pathways. The ability to control the 
multivalent and nanoscale presentation of proteins to cells in a precise manner has thus 
been shown to give us a tool to control and direct cellular functions. 
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CHAPTER 7. FUTURE DIRECTIONS 
I would like to have the principles developed in my thesis work applied to more systems. I 
have developed methods to alter the orientation of antigens on a vaccine particle as well as 
to nanopattern antigens. Both approaches can potentially lead to redirecting the immune 
response to more efficacious epitopes on pathogenic proteins. The future work in this area 
is myriad, but our lab is already pursuing orientation and nanopatterning strategies with the 
Zika envelope DIII protein, malarial pfRH5 and MSP1 and Dengue envelope proteins. 
Additionally, we are looking at alternative methods for nanopatterning HA and controlling 
the orientation of HA. In these developments, we are looking at different scaffold 
architectures for orientation that can better present a desired epitope. We have realized that 
there are many ways to nanopattern protein antigens and that they are not all equal. 
Therefore, there will need to be much future work done to study and understand how to 
best nanopattern proteins to get good blockage of certain epitopes while redirecting the 
response to other regions of the protein.  
The polypeptide scaffolds have the potential to become “off the shelf” scaffolds. Firstly, 
the library size needs to be expanded to more fully span possible valencies and inter-ligand 
spacings. Then it would nice to have scaffolds developed that can bind to more than one 
ligand, and that allow for testing different ratios and spacings of those. When the library of 
scaffolds increased in size and available complexity, I am confident that these scaffolds 
will provide a powerful way to study diverse signaling pathways, better understand 
receptor clustering and signal transduction, and even create designer inhibitors or 
multivalent binders to specific pathogens or pathways. 
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